Question · Q3 2025
Rupesh Parikh asked about the gross margin line, noting improvements over the last two to three quarters, and sought insights into the Q4 outlook and expectations for further improvement. He also inquired about the GLP-1 conversation, specifically the enthusiasm for the pill format and its potential as a bigger tailwind for next year.
Answer
President and CFO Sharon McCollam advised modeling Q4 gross margin more like Q2, explaining that an exceptionally strong Q3 pharmacy business (driven by value-added services and flu/COVID fears) shifted incremental profit from Q4 to Q3, and Q4 pharmacy margin is typically not as strong. Regarding GLP-1s, CEO Susan Morris agreed it could be more of a tailwind with increased accessibility. Sharon McCollam clarified that while the pill version is not broadly used yet and depends on side effects, it is not expected to have a material impact on pharmacy EBITDA in the short term, primarily benefiting patients on the top line.
Ask follow-up questions
Fintool can predict
ACI's earnings beat/miss a week before the call


